Treatment approaches are addressed in each chapter and guideline recommendations are based on systematic reviews of relevant trials. Appraisal of the quality of the evidence and the strength of recommendations followed the GRADE approach. Ongoing areas of controversies and limitations of the evidence are discussed and additional suggestions are also provided for future research. Keywords: cholesterol; chronic kidney disease; clinical practice guideline; dyslipidemia; evidence-based recommendation; KDIGO; systematic review; triglycerides CITATION In citing this document, the following format should be used: Kidney Disease: Improving Global Outcomes (KDIGO) Lipid Work Group. KDIGO Clinical Practice Guideline for Lipid Management in Chronic Kidney Disease. Kidney inter., Suppl. 2013; 3: 259 305. http://www.kidney-international.org & 2013 KDIGO Summary of Recommendation Statements http://www.kidney-international.org & 2013 KDIGO Chapter 1: Assessment of lipid status in adults with CKD 1.1: In adults with newly identified CKD (including those treated with chronic dialysis or kidney transplantation), we recommend evaluation with a lipid profile (total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides). (1C) 1.2: In adults with CKD (including those treated with chronic dialysis or kidney transplantation), follow-up measurement of lipid levels is not required for the majority of patients. (Not Graded) Chapter 2: Pharmacological cholesterol-lowering treatment in adults but not treated with chronic dialysis or kidney transplantation (GFR categories G3a-G5), we recommend treatment with a statin or statin/ezetimibe (GFR categories G1-G2) we recommend treatment with a statin. 